Contemporary use of Selexipag in pulmonary arterial hypertension associated with congenital heart disease: a case series.

ABSTRACT:

Background

There are significant risks of parenteral prostacyclin use in patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD), which may limit their use. Selexipag is an oral, selective prostacyclin analogue that has been shown to reduce disease progression and improve exercise capacity in patients with PAH-CHD. Administering Selexipag in patients with PAH-CHD could potentially overcome some of the risks of parenteral therapy while improving clinical outcomes.

Case summary

We report five cases highlighting the clinical uses of Selexipag in patients with PAH-CHD. In the first two cases, Selexipag was initiated as part of a Treat-to-close strategy. In the third case, initiation of Selexipag improved symptoms and objective exercise ca

SUBMITTER: Blissett S 

PROVIDER: S-EPMC7793171 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature